Alnylam Pharmace. buy Maxi_Scalibusa
Start price
20.01.18
/
50%
€113.72
Target price
16.08.18
€336.00
Performance (%)
-27.30%
End price
16.08.18
€82.67
Summary
This prediction ended on 16.08.18 with a price of €82.67. The prediction for Alnylam Pharmace. disappointed with a performance of -27.30%. Maxi_Scalibusa has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | -2.307% | -2.307% | 48.466% | 50.411% |
| iShares Core DAX® | 0.323% | 2.208% | 21.610% | 72.184% |
| iShares Nasdaq 100 | 0.145% | -0.987% | 5.603% | 112.977% |
| iShares Nikkei 225® | 0.091% | -1.421% | 12.897% | 46.571% |
| iShares S&P 500 | 0.371% | -0.469% | 3.470% | 68.947% |
Comments by Maxi_Scalibusa for this prediction
In the thread Alnylam Pharmace. diskutieren
(Vom Mitglied beendet)